Studies Challenge Assumptions About Sickle Cell Trait and Cardiovascular Health
Dec 08, 2016
Two new studies published in Blood address the need for improved understanding of sickle cell trait (SCT). These studies present valuable data on the cardiovascular health and fitness of individuals with SCT, suggesting that they face no greater risk of heart failure nor have diminished fitness compared to people without the trait.
New Data Shed Light on Potential Advantages of Pacritinib for Patients with Myelofibrosis
Dec 06, 2016
Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to late-breaking study being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego. The study investigators also reported that patients taking a twice-daily dose of this investigational oral multikinase inhibitor experienced significant improvements in symptoms.
Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit
Dec 06, 2016
Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. The study is the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the United States.